Publications by authors named "Richard D Carvajal"

Claim this Profile
I
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Takami Sato, Marcus O Butler, Sophie Piperno-Neumann, Jessica C Hassel, Paul Nathan, Richard D Carvajal

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.
Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik, Van Karlyle Morris, Dan P Zandberg

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients.
Tristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, Antoine Desilets, Rino Seedor, Richard D Carvajal

Oncologist· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. 2021, , 5504.
Alexander N Shoushtari, Shaheer Khan, Kimberly Komatsubara, Lynn Feun, Nicolas Acquavella, Richard D Carvajal

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
Grazia Ambrosini, Catherine Do, Benjamin Tycko, Ronald B Realubit, Charles Karan, Richard D Carvajal

Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific.
Joseph J Sacco, Peter Kirk, Emma Leach, Alexander N Shoushtari, Richard D Carvajal

Cell Rep Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intramedullary primary spinal cord melanoma: illustrative case.
Akash Mishra, Danielle Golub, Daniel Schneider, Shimon Garrel, Harshal A Shah, Richard D Carvajal

J Neurosurg Case Lessons· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.
Angela J Yoon, Richard D Carvajal, Evan M Graboyes, John M Kaczmar, William G Albergotti

Front Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.
Rino S Seedor, Andrew E Aplin, Corine Bertolotto, Richard D Carvajal, Nigel Deacon

Pigment Cell Melanoma Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, Phil F Cheng, Isaac F Hughes, Richard D Carvajal

Eur J Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.
Kymberly D Watt, Stacey Rolak, David P Foley, Jennifer K Plichta, Sandhya Pruthi, Richard D Carvajal

Transplantation· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Individualization for Phase I Cancer Trials With Broadened Eligibility.
Rebecca B Silva, Bin Cheng, Richard D Carvajal, Shing M Lee

Stat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updates in the Management of Uveal Melanoma.
Mali Barbi, Richard D Carvajal, Craig E Devoe

Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S Hong, Lillian L Siu, Richard D Carvajal

Oncoimmunology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Non-cutaneous melanoma: new therapeutic insights.
Ernesto Rossi, Richard D Carvajal

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, Jean-Francois Baurain, Max Schlaak, Richard D Carvajal

N Engl J Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
Lauren M Fahmy, Celine M Schreidah, Diana E McDonnell, Richard D Carvajal, Cynthia M Magro

Dermatol Online J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).
Alexander Z Wei, Lanyi N Chen, Marlana Orloff, Charlotte E Ariyan, Maryam Asgari, Richard D Carvajal

Pigment Cell Melanoma Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scoping review of genetic databases for rare dermatologic diseases: Opportunity for artificial intelligence and machine learning.
Celine M Schreidah, George Bingham Reynolds, Lauren M Fahmy, Richard D Carvajal, Maarten H Vermeer

JAAD Int· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversifying Eligibility to Enhance Real-World Results.
Fatima Fayyaz, Richard D Carvajal, Craig E Devoe

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond.
Lanyi Nora Chen, Richard D Carvajal

Ann Transl Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Richard D Carvajal

Cancer Discov· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma.
Sebastian Bauer, James Larkin, F Stephen Hodi, Frank Stephen, Ellen H W Kapiteijn, Richard D Carvajal

Front Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis